CAR-T cell therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced or metastatic solid tumor (such as bile duct, pancreatic, lung, breast, head/neck, or gynecologic cancer) that has not improved after at least one standard treatment, or for which no standard first-line treatment exists.
- Your tumor tests positive for CD73 or AXL proteins (at least 50% of cells).
- You have at least one measurable tumor on imaging scans.
- You are willing to provide a fresh or stored tumor sample for testing, and possibly undergo a new biopsy during the study.
- Your overall health is good enough for the treatment, as determined by blood tests and heart function checks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
This trial tests a special type of cell therapy called CAR T cells. The cells are changed in the lab to find and attack a protein called CD276 on the surface of solid tumors. If the treatment works, your own immune cells could shrink the tumor or slow its growth.
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.